
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Rebiopsy and loss of HER2 expression
Eric Van Cutsem and colleagues emphasize rebiopsy or ctDNA after progression given spatial and temporal HER2 heterogeneity.
Play episode from 07:38
Transcript


